Carfilzomib (Kyprolis): A Novel Proteasome Inhibitor for Relapsed And/or Refractory Multiple Myeloma.

Galina Perel; Joshua Bliss; Christan M Thomas

首页> 外文期刊>P & T: a peer-reviewed journal for formulary management >Carfilzomib (Kyprolis): A Novel Proteasome Inhibitor for Relapsed And/or Refractory Multiple Myeloma.

【24h】

Carfilzomib (Kyprolis): A Novel Proteasome Inhibitor for Relapsed And/or Refractory Multiple Myeloma.

机译：Carfilzomib（Kyprolis）：一种用于复发和/或难治性多发性骨髓瘤的新型蛋白酶体抑制剂。

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

Key sessions at HemOnc Today covered systemic and locoregional use of immunotherapies. At the cardiology meeting, preventive strategies took center stage.

机译：今天在HemOnc上的关键会议涉及免疫疗法的全身和局部使用。在心脏病学会议上，预防策略占据了中心位置。

著录项

来源
《P & T: a peer-reviewed journal for formulary management》 |2016年第5期|共5页
作者
Galina Perel; Joshua Bliss; Christan M Thomas;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类药学;
关键词

相似文献

外文文献
中文文献
专利

1. Carfilzomib (Kyprolis): A Novel Proteasome Inhibitor for Relapsed And/or Refractory Multiple Myeloma. [J] . Galina Perel, Joshua Bliss, Christan M Thomas P & T: a peer-reviewed journal for formulary management . 2016,第5期

机译：Carfilzomib（Kyprolis）：一种用于复发和/或难治性多发性骨髓瘤的新型蛋白酶体抑制剂。
2. Carfilzomib: A new proteasome inhibitor for relapsed or refractory multiple myeloma [J] . SteeleJ.M. Journal of oncology pharmacy practice: official publication of the International Society of Oncology Pharmacy Practitioners . 2013,第4期

机译：卡非佐米：一种新的蛋白酶体抑制剂，用于复发或难治性多发性骨髓瘤
3. Carfilzomib: A second-generation proteasome inhibitor for the treatment of relapsed and refractory multiple myeloma [J] . ThompsonJ.L. The annals of pharmacotherapy . 2013,第1期

机译：卡非佐米：第二代蛋白酶体抑制剂，用于治疗复发性和难治性多发性骨髓瘤
4. Preincubation with the Proteasome Inhibitor MG-132 Enhances Proteasome Activity via the Nrf2 Transcription Factor in Aging Human Skin Fibroblasts [C] . DAVID CHRISTIAN KRAFT, CUSTER C. DEOCARIS, RENU WADHWA, International Association of Biomedical Gerontology International . 2006

机译：用蛋白酶体抑制剂Mg-132预孵育通过老化人体皮细胞的NRF2转录因子增强蛋白酶体活性
5. A Phase 1/2 Study of Ixazomib as a Replacement for Bortezomib or Carfilzomib for Multiple Myeloma Patients Recently Relapsed or Refractory to Their Last Combination Regimen Containing Either Bortezomib or Carfilzomib [D] . Forouzan, Eli. 2020

机译：Ixazomib的第1/2期作为替代品髓鞘或胭脂瘤患者的替代品的替代物，最近对含有Bortezomib或Carfilzomib的最后组合方案复发或难治
6. Carfilzomib (Kyprolis): A Novel Proteasome Inhibitor for Relapsed And/or Refractory Multiple Myeloma [O] . Galina Perel, Joshua Bliss, Christan M. Thomas 2016

机译：Carfilzomib（Kyprolis）：复发和/或难治性多发性骨髓瘤的新型蛋白酶体抑制剂。
7. A Phase I Single-Agent Study of Twice-Weekly Consecutive-Day Dosing of the Proteasome Inhibitor Carfilzomib in Patients with Relapsed or Refractory Multiple Myeloma or Lymphoma [O] . Melissa Alsina, Suzanne Trudel, Richard R. Furman, 2012

机译：一期单次药剂研究对复发或难治性多发性骨髓瘤或淋巴瘤患者的蛋白酶体抑制剂Carfilzomib的两次连续日给药

Carfilzomib (Kyprolis): A Novel Proteasome Inhibitor for Relapsed And/or Refractory Multiple Myeloma.

摘要

著录项

相似文献

相关主题

期刊订阅